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Objective: We evaluated the effect of transplanted cell type, time, and region of the
heart on transgene expression to determine the potential of combined gene and cell
delivery for myocardial repair.
Methods: Lewis rats underwent myocardial cryoinjury 3 weeks before transplanta-
tion with heart cells (a mixed culture of cardiomyocytes, smooth muscle cells,
endothelial cells and fibroblasts, n  13), vascular endothelial growth factor–
transfected heart cells (n  13), skeletal myoblasts (n  13), vascular endothelial
growth factor–transfected skeletal myoblasts (n 13), or medium (control, n 12).
Vascular endothelial growth factor expression in the scar, border zone, and normal
myocardium was evaluated at 3 days and at 1, 2, and 4 weeks by means of
quantitative polymerase chain reaction. Transplanted cells and vascular endothelial
growth factor protein were identified immunohistologically on myocardial sections.
Results: Vascular endothelial growth factor levels were very low in control scars but
increased transiently after medium injection. Transplantation with heart cells and
skeletal myoblasts significantly increased vascular endothelial growth factor expres-
sion in the scar and border zone. Transplantation of vascular endothelial growth
factor–transfected heart cells and vascular endothelial growth factor–transfected
skeletal myoblasts further augmented vascular endothelial growth factor expression,
resulting in 4- to 5-fold greater expression of vascular endothelial growth factor in
the scar at 1 week. Peak vascular endothelial growth factor expression was greater
and earlier in vascular endothelial growth factor–transfected heart cells than in
vascular endothelial growth factor–transfected skeletal myoblasts. Vascular endo-
thelial growth factor was primarily expressed by the transplanted cells. Some of the
transplanted heart cells and vascular endothelial growth factor–transfected heart
cells were identified in the endothelial layer of blood vessels in the scar.
Conclusions: Transplantation of heart cells and skeletal myoblasts induces vascular
endothelial growth factor expression in myocardial scars and is greatly augmented
by prior transfection with a vascular endothelial growth factor transgene. Vascular
endothelial growth factor expression is limited to the scar and border zone for 4
weeks. Both heart cells and skeletal myoblasts may be excellent delivery vehicles
for cell-based myocardial gene therapy.
Cell transplantation may be a novel therapeutic option for myocar-dial repair in hearts with postinfarction congestive heart failure,unreconstructable coronary atherosclerosis, or cardiomyopathy.1-6We have previously studied the angiogenic effect of transplantationof endothelial cells7 or of a mixed culture of heart cells (predom-inantly cardiomyocytes, with smaller proportions of endothelial
cells, smooth muscle cells, and fibroblasts).8 When these cells were transfected with
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vascular endothelial growth factor (VEGF) 165 ex vivo and
then transplanted into scarred rat hearts, regional blood flow
and vascular densities were significantly greater than those
observed after transplantation of unmodified cells or of
culture medium alone. Ex vivo modification of cells before
transplantation may therefore have the potential to enhance
survival of the transplanted cells and modify their effect on
angiogenesis, matrix remodeling, or restoration of function.
However, the duration of transgene expression after trans-
plantation is unknown and is likely to differ from that
observed after gene transfer alone by means of intramyo-
cardial injection of adenoviral vectors. Long-term or uncon-
trolled expression of angiogenic transgenes has been asso-
ciated with angioma formation.9 Optimal transgene
expression in transplanted cells would therefore be transient
but of sufficient duration to ensure maximal therapeutic
effect. It would also be limited spatially to the zone to which
the transplanted cells were delivered to prevent undesirable
angiogenesis in normal myocardium.
In this series of experiments, we hypothesized that a
VEGF transgene would be expressed only transiently in
cells transplanted into scarred rat hearts and that this VEGF
expression would be limited to the zone of transplantation.
We also evaluated the effect of 2 different cell types to
determine whether there were cell-specific differences in
transgene expression that might influence the suitability of
varying cell types for future therapies.
Methods
Animals and Experimental Model
Animals were syngeneic adult Lewis rats (body weight of 225-250
g for female rats and 250-300 g for male rats; Charles River
Canada Inc, Quebec, Canada). All procedures were approved by
the Animal Care Committee of the University Health Network and
conformed to the guidelines in the “Guide to the Care and Use of
Laboratory Animals” prepared by the National Research Council
and published by the National Academy Press.
A large transmural scar was created in the left ventricular (LV)
free wall of rat hearts by means of a cryoinjury technique, as
previously described.8 Briefly, through a left lateral thoracotomy,
the LV free wall was exposed, and cryoinjury was performed by
means of 12 one-minute applications of an 8  10–mm elliptical
metal probe cooled to 196°C by means of immersion in liquid
nitrogen. After recovery, the cryoinjured rats were randomly di-
vided into 5 experimental groups: control, injected with culture
medium alone (control, n  12), transplantation with a mixed
culture of unmodified heart cells (HC group; n  13), transplan-
tation with VEGF-transfected heart cells (HC group; n  13),
transplantation with unmodified skeletal myoblasts (Sk group; n
13), or transplantation with VEGF-transfected skeletal myoblasts
(Sk group; n  13).
Cell Isolation and Culture
A mixed primary culture of cardiomyocytes, smooth muscle cells,
endothelial cells, and fibroblasts was isolated from the left ventri-
cles of donor rats, as previously described.8 The cultured cells
were depleted of fibroblasts by means of a preplating technique
and then maintained in Iscove’s modified Dulbecco’s medium
(IMDM) containing 10% fetal bovine serum (FBS) for 5 to 7 days
before transfection and transplantation. In a subset of plates, 69%
of cells stained positively for myosin heavy chain and were as-
sumed to be cardiomyocytes, 14% of cells stained positively for
-smooth muscle actin and were assumed to be smooth muscle
cells, and 12% of cells stained positively for Factor VIII and were
assumed to be endothelial cells. The remaining cells were assumed
to be fibroblasts.
Primary skeletal myoblasts were isolated and cultured by
means of a modified, single muscle fiber culture technique.10
Briefly, 3 g of muscle from the quadriceps femoris muscle of adult
Lewis rats underwent enzymatic digestion with protease and type
I collagenase (Sigma, St Louis, Mo) before isolation and resus-
pension of single intact muscle fibers in IMDM containing 10%
FBS. After preplating, single skeletal muscle fibers were plated
onto laminin-coated plates (Becton Dickinson Labware, Bedford,
Mass). Skeletal myoblasts dissociated from the muscle fibers,
attached to the plate, and were allowed to proliferate for 48 to 72
hours, as the original muscle fibers underwent cell death and lysis.
The skeletal myoblasts were maintained in IMDM containing 10%
FBS for a further 5 to 7 days and then transfected before fusion and
myotube formation.
Cell Transfection
Skeletal myoblasts and heart cells were transfected in 100-mm
dishes at 60% to 70% confluence. Cells were transfected ex vivo
by means of a lipid-based technique, with a plasmid encoding
VEGF165 (pCEP4-VEGF), as previously described.8 Transfection
efficiencies were monitored in a subset of plates by means of
cotransfection with pEGFP-N2 (BD Biosciences Clontech, Palo
Alto, Calif), a plasmid expressing green fluorescence protein. Cells
were incubated with the transfection reagents for 24 hours before
transplantation.
Bromodeoxyuridine Prelabeling
A subset of the plates (1 of every 4 plates) of skeletal myoblasts
and heart cells was prelabeled with bromodeoxyuridine (BrdU) 2
days before transplantation and 1 day before transfection (when
applicable) to facilitate identification of transplanted cells in the
recipient hearts.8 Preliminary evaluation of BrdU uptake efficiency
in these plates of cells indicated that approximately 60% of the
cultured cells stained positively for BrdU. In histologic sections of
the rat hearts in the transplanted groups, a monoclonal antibody
against BrdU was used to identify the transplanted cells within the
recipient hearts.
Cell Transplantation
Rats underwent cell transplantation 3 weeks after cryoinjury of the
LV free wall. VEGF-transfected or VEGF-untransfected heart
cells or skeletal myoblasts were detached from culture dishes with
trypsin, centrifuged, and resuspended in serum-free medium. After
induction of general anesthesia, rat hearts were exposed through a
midline sternotomy. Three million cells in 0.05 mL of serum-free
medium were injected at multiple points into the center of the
cryoinjury-induced LV scar with a tuberculin syringe. The same
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volume of culture medium without cells was injected into the scars
of control rats.
Rats were put to death, and the hearts were excised 3 days (n
 15), 1 week (n  15), 2 weeks (n  15), and 4 weeks (n  19)
after cell transplantation. The atria and the right ventricular free
wall were excised, leaving the left ventricle, which was divided
into the scar zone (consisting of the transmural scar), the border
zone (partial-thickness scar containing both fibrous tissue and
surviving muscle), and the normal area. A portion of each zone
was fixed in formalin for histologic evaluation, and the rest of the
tissue was frozen in liquid nitrogen for analysis of gene expression.
RNA Isolation and Reverse Transcription
Myocardial specimens were snap-frozen in liquid nitrogen and
powdered. A portion of each specimen was used immediately for
total RNA isolation, whereas the remainder was stored at 80°C
for subsequent analysis of protein levels. Total RNA was isolated
with TRIzol RNA extraction reagents (Invitrogen Corp, Carlsbad,
Calif), according to the manufacturer’s specifications. Messenger
RNA in this specimen was reverse transcribed to single-strand
cDNA with SuperScript II reverse transcriptase (Invitrogen Corp).
Briefly, 10 g of total RNA was mixed with 1 g of oligo (dT)
20-mer at 65°C and incubated for 5 minutes. The sample was
placed on ice, and 4 L of 5 first-strand buffer, 2 L of 10
mmol/L dithiothreitol, 40 units of RNase inhibitor, and 400 units
of SuperScript II reverse transcriptase were added to a 20-L final
reaction volume. The mixture was incubated at 42°C for 60 min-
utes, followed by enzyme inactivation at 70°C for 15 minutes. The
reverse transcribed cDNA was stored at 20°C for later use.
Quantitation of VEGF mRNA by Means of Real-Time
Polymerase Chain Reaction
Quantitation of VEGF mRNA expression was carried out by
means of real-time polymerase chain reaction (PCR) on the 9700
HT System (Applied Biosystems Inc, Foster City, Calif). Two
pairs of specific PCR primers were designed on the basis of VEGF
sequences from the GeneBank (National Center for Biotechnology
Information) to accurately evaluate the molecular weight of the
PCR products. One primer (antisense, 5'-TGAAGGTCGGAGT-
CAACGGATTT-GGT-3'; sense, 5'-CATGTGGGCCATGAG-
GTCCACCAC-3') generated a 277-bp sequence, and the other
(antisense, 5'-TCATGGTTGTCTATCAGCGCAG-3'; sense, 5'-
GCACACAG-GATGGCTTGAAGAT-3') generated a 107-bp
fragment located within the 277-bp sequence.
Standard PCR was first performed with these 2 primers by
using the single-strand cDNA from the sample as a template. Gel
electrophoresis confirmed that the PCR products comprised a
single band of the correct size. This band was excised, and the
PCR product was purified from the gel and then sequenced to
confirm its identity as the VEGF coding sequence. The purified
277-bp product was quantitated spectrophotometrically for use as
a standard for subsequent real-time PCR assays.
Real-time PCR was performed on experimental samples and
the VEGF standards by using the 107-bp VEGF primers with the
Master Mix SYBR Green I Kit (Applied Biosystems Inc, Foster
City, Calif) by using 3-fold serial dilutions of VEGF standards in
dd-water to generate standards ranging from 1500 to 0.23 pg.
cDNA samples from the experimental animals were diluted 200-
fold, and 5 L of each standard or sample was transferred to a
96-well PCR plate. Each assay was performed in duplicate, and 5
L of dd-water was assayed as a no-template control. Five micro-
liters of a 5 pmol VEGF sense and antisense primer mixture
(producing a 107-bp product) and 10 L of Master SYBR Green
I Mix were added to each well. The reaction sequence included
stabilization for 2 minutes at 50°C and denaturation for 10 minutes
at 95°C before 40 cycles of denaturation for 15 seconds at 95°C,
annealing for 15 seconds at 60°C, extension for 1 minute at 72°C,
and dissociation for 15 seconds at 95°C, 15 seconds at 65°C, and
15 seconds at 95°C. Real-time PCR data were analyzed with SDS
2.1 software (Applied Biosystems Inc, Foster City, Calif). Results
are reported as molecular copies of VEGF per microgram of total
RNA.
Quantitation of VEGF Protein
VEGF protein in the scar, border zone, and normal myocardium
was quantitated by means of chemiluminescent slot blot analysis
(MiniFold II; Schleicher & Schuell Inc, Keene, NH), as previously
described.8
Histologic and Immunohistochemical Assays
Myocardial specimens were fixed in formalin, embedded in par-
affin, and sectioned into 6-m-thick slices. One slide of each
sample was stained with hematoxylin and eosin for morphologic
evaluation of the scar and transplanted cells. Immunohistochemi-
cal staining with monoclonal antibodies directed against BrdU,
Factor VIII, or VEGF was performed to localize the transplanted
cells, VEGF protein, and vascular spaces. Slides were deparaf-
finized in xylene and rehydrated in graded ethanol, immersed in
3% H2O2 in 70% methanol to inhibit endogenous peroxidase, and
incubated in 0.2% of Triton X-100. Nonspecific protein binding
was blocked with 2% normal goat serum and 150 L of primary
antibodies against BrdU (1:2000), Factor VIII (1:1000), VEGF
(1:3000), or phosphate-buffered saline (PBS; as a negative control)
was added before incubation at 4°C overnight. Slides were washed
to remove unbound primary antibodies, and a biotin-labeled sec-
ondary antibody (1:2500; BioRad Laboratories, Richmond, Calif)
was added. After washing, sections were incubated with an avidin-
biotin complex conjugated with peroxidase. Visualization was
performed with a diaminobenzidine solution. Cellular nuclei were
counterstained with hematoxylin for 1 minute, and the samples
were then covered with crystal mounts and photographed.
VEGF protein and the transplanted cells were also identified
and localized by means of immunohistochemical double staining
with a laser confocal microscopy system (Bio-Rad, Richmond,
Calif), according to the manufacturer’s protocols (Molecular Probe
Inc, Eugene, Ore). Briefly, the slides were treated with 3% H2O2
in 70% methanol, incubated in 0.2% Triton X-100, and blocked
with 2% normal goat serum after rehydration. Slides were incu-
bated with fluorescein isothiocyanate–labeled anti-BrdU antibod-
ies (1:100), phycoerythrin-labeled anti-VEGF antibodies (1:100),
or both overnight at 4°C. Unbound antibodies were washed away
with PBS. Slides were treated with 10 mg/mL RNase (Qiagen,
Mississauga, Ontario, Canada) for 30 minutes at room tempera-
ture, washed with PBS, and incubated for 5 minutes in 4,6-
diamino-2-phenylindole (DAPI) diluted 1:300 in PBS to stain both
host and donor cell nuclei. The fluorescein isothiocyanate, phyco-
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erythrin, and DAPI fluorescent emissions were detected by using
laser detectors at 488 nm, 575 nm, and 461 nm wavelengths,
respectively, and observable under confocal microscopy as green,
red, and blue fluorescent signals.
Statistical Analysis
To evaluate the determinants of VEGF expression levels, we first
analyzed the effect of group, time, and location by means of
analysis of variance with SAS statistical software (Cary, NC).
Both main effects and interactive effects (group  time, group 
location, time  location, and group  time  location) were
evaluated.
A second analysis was performed on the 4 cell-transplanted
groups to statistically evaluate the effect of VEGF transfection and
cell type rather than group assignment in general, evaluating the
effects of VEGF transfection (yes-no), cell type (heart cells–
skeletal myoblasts), time, and location by means of analysis of
variance. Again, main effects and all 2-way interactive effects
(VEGF  cell type, VEGF  time, VEGF  location, cell type 
time, cell type  location, and time  location) were modeled.
Nonsignificant interactive effects were discarded, and the final
model included only the 4 main effects and the statistically sig-
nificant interactive effects.
Because of the large number of data points incorporated in this
analysis and the multiple comparisons that could theoretically be
performed (between 5 groups, 4 time points, and 3 regions), we
deliberately avoided statistical analysis of subsets of these data (eg,
assigning a P value to the comparison of the HC group with the
other groups at the 1-week time point in the scar region). The very
large number of potential subset analyses of this type would have
entailed a very high probability of a type I error. Instead, we chose
to present the data graphically, depicting means and SDs, to
visually depict obvious differences or lack of differences in the
context of the overall analysis of main and interactive effects
described previously. In addition, overall effects of a specific
factor (eg, the effect of experimental group across all time points
and all zones studied) were subjected to the Duncan multiple-range
test to identify differences in VEGF mRNA levels related to a
specific predictor.
Results
VEGF Expression: Overall Effects of Group, Time,
and Zone
VEGF mRNA levels in the scar, border zone, and normal
area at 3 days and 1, 2, and 4 weeks are depicted in Figure
1 for the 4 cell-transplanted groups and the control group.
As anticipated, all overall main effects were highly signif-
icant (group, time, and zone effects: all P  .0001). All
interactive effects were also highly significant (group 
time, group  location, time  location, and group  time
 location effects: all P  .0001). Overall VEGF mRNA
and protein levels were significantly higher in the HC and
Sk groups than in the HC and Sk groups (P  .05), which
were again greater than those in the control group (P .05).
Overall VEGF mRNA and protein levels were significantly
higher in the scar and border zone than in the normal
myocardium (P  .05).
When the 4 cell-transplanted groups were analyzed with-
out the control group, to determine the effects of cell type
and VEGF transfection on VEGF expression, the effects of
transfection, time, and zone were all highly significant (P
.0001), whereas the effect of cell type was not (P  .8). All
interactive effects except transfection  cell type (P  .13)
were significant (P  .05).
VEGF Expression: Effect of Cell Transplantation
Alone
VEGF mRNA and protein levels in the scars of control rat
hearts injected only with medium were extremely low (Fig-
ure 1). VEGF mRNA expression in control rats was slightly
greater at 3 days than at 1, 2, or 4 weeks. Levels in control
hearts at 1, 2, and 4 weeks were similar. In hearts trans-
planted with unmodified heart cells or skeletal myoblasts,
VEGF mRNA expression was greater than that in control
rats at 3 days and 1 and 2 weeks (Figure 1). Peak VEGF
mRNA expression in hearts transplanted with unmodified
cells (heart cells or skeletal myoblasts) occurred at 3 days in
both groups. VEGF mRNA expression was greater in the
scar than in the border zone at 3 days and 1 and 2 weeks in
the HC and Sk groups, whereas expression levels in normal
myocardium in the HC and Sk groups were similar to those
in the control group at all time points studied. By 4 weeks,
VEGF mRNA expression had decreased in the scar and
border zones of the hearts of the HC and Sk groups to levels
that were similar to those observed in the control group.
VEGF Expression: Effect of Ex Vivo Transfection
with VEGF
Prior ex vivo transfection with a VEGF transgene in the
HC and Sk groups was associated with dramatically
increased levels of VEGF mRNA and protein expression in
the scars and border zones of these hearts compared with
HC, Sk, or control hearts at 3 days and 1 and 2 weeks
(Figure 1). The overall effect of VEGF transfection on
VEGF mRNA and protein levels in the cell-transplanted
groups was highly significant (P  .0001). VEGF mRNA
and protein expression in the HC and Sk groups was
substantially greater in the scar than in the border zone at 3
days and 1 and 2 weeks. By 4 weeks, VEGF mRNA and
protein levels had decreased and were similar to those in the
control group. VEGF mRNA levels in the normal myocar-
dium were similar in all groups at all times.
VEGF Expression: Effect of Cell Type
Peak VEGF mRNA expression in the scar areas of the HC
hearts was observed at 3 days compared with 7 days for the
Sk hearts (Figure 1, A and B). Maximum VEGF mRNA
levels appeared to be greater in the scar areas of the HC
hearts (at 3 days) than in the Sk hearts (at 1 week). In
contrast, VEGF mRNA expression in the border zone ap-
peared to be greater in the Sk hearts at 1 week than in the
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HC hearts (Figure 1, B). Although the overall effect of
cell type on VEGF mRNA expression in cell-transplanted
hearts was not significant (P  .8), significant interactive
effects of cell type  time (P  .02) and cell type  zone
(P  .01) were noted.
Colocalization of VEGF Expression with Transplanted
Cells
Transplanted cells were localized within the myocardial
scar in all cell-transplanted hearts by means of immunohis-
tochemical staining with monoclonal antibodies directed
against BrdU (Figure 2, A), as well as by means of confocal
microscopy of sections stained with both green fluorescen-
ce–tagged antibodies against BrdU and blue fluorescence–
tagged DAPI labeling of all cell nuclei (Figure 2, B). Pho-
tomicrographs of hearts stained with green fluorescence–
tagged antibodies against BrdU and red fluorescence–
tagged antibodies against VEGF demonstrated that VEGF
was being expressed in the transplanted cells (Figure 2, C).
The degree of staining for VEGF was qualitatively more
intense in the HC and Sk groups at 3 days and 1 week,
which is consistent with the real-time PCR observations.
Angiogenesis
Vascular spaces lined with Factor VIII–positive cells were
observed in the scars and border zones of all rat hearts but
were qualitatively fewer in the control hearts, intermediate
in the HC and Sk hearts, and greatest in the HC and Sk
hearts. BrdU-positive endothelial cells were identified in
blood vessels within the scars of HC hearts and, to a lesser
extent, within the scars of HC hearts (Figure 3) but were not
apparent in the other groups.
Discussion
In this study our quantitative PCR results indicated that
VEGF expression in the hearts transplanted with VEGF-
transfected heart cells and VEGF-transfected skeletal myo-
blasts was dramatically greater than in hearts transplanted
with unmodified heart cells and skeletal myoblasts. In all
Figure 1. VEGF mRNA expression in rat hearts transplanted with heart cells (HC), VEGF-transfected heart cells
(HC), skeletal myoblasts (Sk), VEGF-transfected skeletal myoblasts (Sk), or medium alone (Ctrl) evaluated by
means of quantitative PCR at 3 days (A), 1 week (B), 2 weeks (C), or 4 weeks (D). Transplantation with heart cells
and skeletal myoblasts induced greater VEGF expression than that of the control hearts, and VEGF mRNA levels
in HC and Sk hearts were markedly increased over those in the HC and Sk groups. VEGF expression was
greatest in the scar, intermediate in the border zone, and did not differ from control values in the normal
myocardium. Expression was limited to 4 weeks.
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cell-transplanted hearts, however, VEGF expression was
temporally limited to a 4-week period after transplantation.
We deliberately used a technique of gene transfer in which
transient rather than long-term expression would be antici-
pated. Because persistent or uncontrolled VEGF expression
might result in excessive angiogenesis or angioma forma-
tion,9 a limited duration of transgene expression may pro-
vide greater safety while still achieving the desired angio-
genesis. Histologic examination did not reveal any evidence
of angioma formation as a result of this gene delivery
strategy at the time points studied.
The 4-week duration of transgene expression observed
with these ex vivo transfected cells compares with the
approximately 1- to 4-week duration of expression reported
after adenoviral transfection techniques of direct gene trans-
fer without cell transplantation. Host immune responses to
the adenoviral vectors are thought to limit the duration of
expression in such delivery strategies.11-13 In these experi-
Figure 2. Laser confocal micrographs of serial sections of the scar of a rat heart transplanted with VEGF-
transfected heart cells (HC) after DAPI (blue) staining of all cell nuclei (A), BrdU (green) staining of transplanted
cell nuclei (B), DAPI (blue) staining of all cell nuclei and VEGF (red) staining (C), or BrdU (yellow) staining of
transplanted cell nuclei and VEGF (red) staining (D). (Original magnification 1000.) DAPI-positive and BrdU-
positive nuclei (white arrows) represent transplanted cells. DAPI-positive and BrdU-negative nuclei (yellow
arrows) might represent either BrdU-unlabeled transplanted cells or host cells. Cytoplasmic VEGF protein (red)
surrounds both the BrdU-positive nuclei and the smaller number of BrdU-negative nuclei.
Figure 3. Conventional light photomicrograph of the scar of a rat
heart transplanted with VEGF-transfected heart cells (HC) after
immunostaining for BrdU. BrdU-positive transplanted cells (ar-
rows) are observed in the endothelial cell layer of this capillary.
(Original magnification 600.)
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ments we attempted to minimize the immune response to
the transplanted cells by using syngeneic donor cells. No
immunosuppressive therapy was administered to these rats,
and we did not observe any histologic evidence of an
immune response, such as a lymphocytic infiltrate. Such an
immune response could, however, occur because of the
transplanted cells, the technique of DNA transfer, or an
immunogenic transgene product. We used a lipid-based,
rather than viral, technique of DNA transduction to mini-
mize potential host responses to viral proteins. Obviously, if
this technique of ex vivo gene transfer before cell transplan-
tation resulted in increased immunogenicity and therefore
led to the eventual rejection of the transplanted cells, it
would be of very limited utility. Care will therefore have to
be taken in future studies to select gene products that are not
significantly antigenic.
Suzuki and colleagues14 have previously reported that
skeletal myoblasts transduced with VEGF through hemag-
glutinating virus of Japan liposome and transplanted into the
border zone of a circumflex artery infarct resulted in in-
creased VEGF expression in whole LV specimens. They did
not, however, examine the spatial distribution of this VEGF
expression to determine whether inappropriate expression
occurred in normal myocardium. In our current study en-
hanced VEGF expression was spatially limited to the scars
and border zones of cell-transplanted hearts, regardless of
the presence or absence of prior transfection with a VEGF
transgene. In all cell-transplanted groups and at all times,
VEGF levels in the scars were higher than levels in the
border zones. VEGF mRNA levels in the normal myocar-
dium were similar to control levels in all groups at all time
points. At thoracotomy, donor cells were injected into mul-
tiple sites in what appeared visually to be the center of the
scar and its immediate surroundings. At the time of histo-
logic evaluation, transplanted cells were observed through-
out the scar and, to a lesser degree, in the border zone. The
local prevalence of the transplanted cells appeared to cor-
relate with the level of VEGF expression, and confocal
microscopy confirmed that VEGF expression was localized
to the transplanted cells. It is likely, however, that a low
level of VEGF expression will take place in host cells that
have absorbed VEGF-coding plasmids from donor cells that
die and undergo lysis after transplantation.
Interestingly, we also observed a low but distinct in-
crease in VEGF expression at 3 days in control hearts in
which only serum-free culture medium, without cells, was
injected. This likely represents a response to the local
trauma of injection and may be analogous to the angiogenic
response to mechanical or laser perforation of the myocar-
dium. Under the conditions used in this study, however, this
response was dwarfed by the effects of cell transplantation
and of VEGF gene transfer.
In this study peak VEGF expression occurred earlier in
HC hearts than in Sk hearts (3 days vs 7 days), and peak
VEGF levels were greatest in HC hearts. In contrast,
VEGF levels in the border zone at 1 week appeared to be
greater with Sk than HC hearts. Although the degree of
angiogenesis induced by means of cell transplantation may
represent an important determinant of transplanted cell sur-
vival and ultimate efficacy, it is unclear as to whether the
differences in peak VEGF expression observed between
heart cells and skeletal myoblasts in this study will have a
significant effect on cell survival. Heart cells and skeletal
myoblasts may also have differential susceptibilities to the
ischemic conditions in the scar or differential survival rates
after transplantation for other reasons, and the importance of
this finding therefore remains unknown.
Histologic evaluation revealed BrdU-positive cells in the
endothelial layer of capillaries and arterioles in the scars and
border zones of HC and HC hearts, but not in the other
groups. These cells are probably derived from the endothe-
lial cell population in the mixed cultures of heart cells and
VEGF-transfected heart cells used in this study. We did not
expect, and did not observe, BrdU-positive endothelial cells
in the Sk and Sk groups.
In summary, our study demonstrated that ex vivo trans-
fection of either a mixed culture of heart cells or of skeletal
myoblasts with a VEGF-encoding plasmid was associated
with dramatically increased levels of VEGF mRNA expres-
sion. This VEGF expression occurred primarily in trans-
planted cells and was spatially limited to the scars and
border zones of the rat hearts and temporally limited to a
4-week duration. These patterns of transgene expression
suggest that both heart cells and skeletal myoblasts may be
appropriate delivery vehicles for therapeutic transgenes. We
are currently evaluating the effect of this VEGF transgene
on survival of the transplanted cells, the durability of the
angiogenic response, and its safety profile over a longer
follow-up period. Transplantation of cells transfected with
multiple genes to promote angiogenesis, to enhance inte-
gration with host cells,15 or to minimize apoptosis16 may
ultimately prove to be the most promising therapeutic ap-
plication of cell transplantation.
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